Olaparib and bevacizumab: On the horizon for treating ovarian cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Suresh Kumarasamy, MBBS(Mysore), MObGyn(Mal), FRCOG(Lond), FRCP(Ire), AM, from Gleneagles Penang, Penang, Malaysia, reviews advances in the development of new therapeutic approaches for the management of patients with ovarian cancer, including the available data and future directions of new agents, olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and bevacizumab, an anti-VEGF antibody.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews